View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Mar. 31, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS INC
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 106,054,648
Entity Common Stock, Shares Outstanding		91,173,443
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$ 23,726	$ 25,777
Investments - Certificates of deposit	0	4,980
Accounts receivables	144	0
Inventories	1,105	0
Prepaid expenses and other current assets	1,457	1,231
Total current assets	26,432	31,988
Property, plant and equipment, net	4,042	3,253
Total assets	30,474	35,241
Current liabilities
Accounts payable	939	925
Accrued expenses	5,790	5,473
Warrant liability	3,427	2,439
Total current liabilities	10,156	8,837
Deferred revenue	309	300
Commitments and contingencies
Stockholders' equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2012 and 2011	0	0
Common stock, $.01 par value; 170,000,000 shares authorized; 76,849,033 and 48,237,630 shares issued and 76,820,933 and 48,016,002 outstanding at December 31, 2012 and December 31, 2011, respectively	768	482
Additional paid-in capital	218,063	172,613
Accumulated deficit	(198,808)	(146,940)
Treasury stock, at cost; 28,100 shares at December 31, 2012 and December 31, 2011	(51)	(51)
Accumulated other comprehensive income	37	0
Total stockholders' equity	20,009	26,104
Total liabilities and stockholders' equity	$ 30,474	$ 35,241

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2012	Dec. 31, 2011
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	76,849,033	48,237,630
Common stock, shares outstanding (in shares)	76,820,933	48,209,530
Treasury stock, at cost (in shares)	28,100	28,100

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements of Comprehensive Loss [Abstract]
Revenue	$ 346	$ 0	$ 0
Costs of goods sold	(39)	0	0
Gross profit	307	0	0
Operating expenses
Selling, general and administrative	27,963	21,283	13,187
Research and development	26,215	25,173	17,556
Total operating expenses	54,178	46,456	30,743
Operating loss	(53,871)	(46,456)	(30,743)
Change in fair value of warrant liability, net	2,159	15,566	(15,951)
Interest income	19	5	10
Other expense and interest expense	(175)	0	0
Net Loss	$ (51,868)	$ (30,885)	$ (46,684)
Common share data:
Basic and diluted loss per share (in dollars per share)	$ (0.85)	$ (0.68)	$ (1.2)
Weighted average number of basic and diluted common shares outstanding (in shares)	61,275,527	45,236,921	38,991,481
Other comprehensive income (loss):
Foreign currency translation adjustments	$ 37	$ 0	$ 0
Unrealized loss on securities	0	26	(10)
Other comprehensive income (loss), total	37	26	(10)
Comprehensive loss	$ (51,831)	$ (30,859)	$ (46,694)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]	Total
Balance at Dec. 31, 2009	$ 362	$ (51)	$ 92,835	$ (69,371)	$ (16)	$ 23,759
Balance (in shares) at Dec. 31, 2009	36,223,097	(28,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	3,839	0	0	3,839
Compensation expense for issuance of restricted stock	$ 4	$ 0	1,671	0	0	1,675
Compensation expense for issuance of restricted stock (in shares)	414,042	0
Exercise of warrants and options, common stock surrendered upon restricted stock vesting	$ 12	$ 0	3,830	0	0	3,842
Exercise of options, common stock surrendered upon restricted stock vesting (in shares)	1,206,007	0
Sale of common stock, net of expenses	$ 52	$ 0	33,454	0	0	$ 33,506
Sale of common stock, net of expenses (in shares)	5,185,000	0				5,185,000
Change in unrealized loss on investments	$ 0	$ 0	0	0	(10)	$ (10)
Fair value of warrants reclassified from liability to additional paid-in capital upon exercise	0	0	9,154	0	0	9,154
Foreign currency translation						0
Net loss	0	0	0	(46,684)	0	(46,684)
Balance at Dec. 31, 2010	$ 430	$ (51)	144,783	(116,055)	(26)	29,081
Balance (in shares) at Dec. 31, 2010	43,028,146	(28,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	3,605	0	0	3,605
Compensation expense for issuance of restricted stock	$ 2	$ 0	652	0	0	654
Compensation expense for issuance of restricted stock (in shares)	173,212	0
Exercise of warrants and options, common stock surrendered upon restricted stock vesting (in shares)	36,272	0
Exercise of options, common stock surrendered upon restricted stock vesting	$ 0	$ 0	82	0	0	82
Sale of common stock, net of expenses	$ 50	$ 0	23,491	0	0	$ 23,541
Sale of common stock, net of expenses (in shares)	5,000,000	0				5,000,000
Change in unrealized loss on investments	$ 0	$ 0	0	0	26	$ 26
Foreign currency translation						0
Net loss	0	0	0	(30,885)	0	(30,885)
Balance at Dec. 31, 2011	$ 482	$ (51)	172,613	(146,940)	0	26,104
Balance (in shares) at Dec. 31, 2011	48,237,630	(28,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	2,807	0	0	2,807
Compensation expense for issuance of restricted stock	$ 4	$ 0	1,014	0	0	1,018
Compensation expense for issuance of restricted stock (in shares)	408,687	0
Sale of common stock, net of expenses	$ 252	$ 0	36,995	0	0	$ 37,247
Sale of common stock, net of expenses (in shares)	25,227,259	0				15,333,340
Change in unrealized loss on investments						$ 0
Exercise of warrants	$ 30	$ 0	4,404	0	0	4,434
Exercise of warrants (in shares)	2,975,457	0
Fair value of warrants reclassified from liability to additional paid-in capital upon exercise	$ 0	$ 0	908	0	0	908
Fair value of warrants issued classified as liability	0	0	(678)	0	0	(678)
Foreign currency translation	0	0	0	0	37	37
Net loss	0	0	0	(51,868)	0	(51,868)
Balance at Dec. 31, 2012	$ 768	$ (51)	$ 218,063	$ (198,808)	$ 37	$ 20,009
Balance (in shares) at Dec. 31, 2012	76,849,033	(28,100)

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net loss	$ (51,868)	$ (30,885)	$ (46,684)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	2,807	3,605	3,839
Restricted stock and warrant compensation expense	1,018	654	1,675
Depreciation expense	1,331	1,035	472
Loss on disposal of equipment	0	0	7
Warrant liability fair value adjustment	(2,159)	(15,566)	15,951
Non-cash interest income	2	0	(3)
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	(228)	553	(1,001)
Decrease in investment in common stock	0	26	10
Decrease (increase) in accounts receivable	(144)
Decrease (increase) in inventories	(1,105)	0	0
Increase (decrease) in accounts payable and accrued expenses	331	3,206	1,351
Deferred revenue	9	0	300
Net cash used in operating activities	(50,006)	(37,372)	(24,083)
Cash flows from investing activities:
Purchase of property, plant, and equipment	(2,120)	(2,607)	(1,638)
Purchase of short-term investments and marketable equity securities	0	(4,980)	(3,235)
Proceeds from maturities of short-term investments	4,980	1,492	1,743
Net cash (used in) provided by investing activities	2,860	(6,095)	(3,130)
Cash flows from financing activities:
Net proceeds from sale of stock and exercise of stock options and warrants	45,058	23,623	37,348
Net cash provided by financing activities	45,058	23,623	37,348
Foreign currency effects on cash	37	0	0
(Decrease) increase in cash and cash equivalents	(2,051)	(19,844)	10,135
Cash and cash equivalents at beginning of period	25,777	45,621	35,486
Cash and cash equivalents at end of period	23,726	25,777	45,621
Supplemental non-cash activities:
Cashless exercise of stock options and shares surrendered upon restricted stock vesting		(61)	700
Fair value of warrants issued	4,055	0	0
Fair value of warrants reclassified from liability to additional paid-in capital upon exercise	$ 908	$ 0	$ 9,154

Description of Business

12 Months Ended

Dec. 31, 2012

Description of Business and Summary of Significant Accounting Policies [Abstract]

Description of Business and Summary of Significant Accounting Policies

(1)

Description of Business and Summary of Significant Accounting Policies

We are a specialty pharmaceutical and medical device company focused on oncology. Our proprietary technology is designed to administer high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. Our initial focus is on the treatment of primary and metastatic liver cancers. We believe that the proprietary technology is a platform that may have broader applicability, including the use of other drugs to treat the liver, as well as for the treatment of cancers in other organs and regions of the body. In 2010, we announced that our randomized Phase 3 clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. We have also completed a multi-arm Phase 2 trial to treat other liver cancers.

Outside of the United States, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT Delivery System for Melphalan). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT System for Melphalan in Europe. In October 2012, we satisfied all of the requirements to affix the CE Mark to the Hepatic CHEMOSAT Delivery System device for intra-hepatic arterial delivery and extracorporeal filtration of doxorubicin hydrochloride injection (CHEMOSAT System for Doxorubicin).

In the United States, our proprietary system for the administration of melphalan hydrochloride to the liver is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). We submitted our New Drug Application (NDA) to the FDA on August 15, 2012, with the proposed trade name Melblez KitTM (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) (Melblez Kit), and are seeking approval for commercial sale of the Melblez Kit in the treatment of patients with unresectable metastatic ocular melanoma in the liver. Our NDA was accepted for filing by the FDA on October 15, 2012 and has been designated for standard review with a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2013.

The CHEMOSAT/Melblez Kit system administers concentrated regional chemotherapy to the liver. This "whole organ" therapy is performed by first isolating the circulatory system of the liver, deliver chemotherapeutic agent, and filtering the blood prior to returning it to the patient. During the procedure, three catheters are placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver from the body's circulatory system, administer a 30 minute infusion of the chemotherapeutic agent melphalan hydrochloride directly to the liver, and collect drug-laden blood exiting the liver for filtration by proprietary filters. The filters reduce the concentration of chemotherapeutic agent in the blood, thereby minimizing systemic exposure to the drug and related toxic side-effects before the filtered blood is returned to the patient's circulatory system. Through December 31, 2012, the CHEMOSAT/Melblez Kit system has been used on approximately 200 patients through clinical development and early commercial experience in Europe.

The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through 2013, but anticipates that additional working capital may be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing or sales experience; and dependence on key personnel.

Basis of Condensed Consolidated Financial Statement Presentation

12 Months Ended

Dec. 31, 2012

Basis of Condensed Consolidated Financial Statement Presentation [Abstract]

Basis of Condensed Consolidated Financial Statement Presentation

(2)

Basis of Condensed Consolidated Financial Statement Presentation

The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company's consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(3)

Summary of Significant Accounting Policies

Use of Estimates

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company's condensed consolidated balance sheets and the amount of expenses reported for each of its periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

Cash Equivalents and Concentrations of Credit Risk

The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

Investments

Management determines the appropriate classification of securities at the time of purchase and reevaluates such classification as of each balance sheet date. The Company's securities are classified as either available-for-sale or held-to-maturity. Investments classified as held-to-maturity are stated at amortized cost. Investments classified as available-for-sale are stated at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders' equity.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. As the Company's commercial activities expand, collections and payments from customers will be monitored and a provision for estimated credit losses will be created based upon historical experience and specific customer collection issues that may be identified. At December 31, 2012 there were no accounts receivable determined to be uncollectable.

Inventories

Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. As of December 31, 2012, there are no reserves for expired, obsolete, or slow-moving inventory.

Prior to obtaining authorization to affix the CE Mark to its Generation Two Delcath Hepatic CHEMOSAT® Delivery System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2012 includes finished goods and components relating to Generation Two of the Delcath Hepatic CHEMOSAT® Delivery System that have been purchased since April 2012. Therefore, as is common for companies transitioning from the development stage to commercial, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company's cost of goods sold will be adjusted accordingly.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2012 and 2011, the Company did not have any derivative instruments that were designated as hedges.

Fair Value Measurements

The Company adopted ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Deferred Revenue

Deferred revenue on the accompanying consolidated balance sheets includes payment received upon execution of a research and distribution agreement with Chi-Fu Trading Co, Ltd. and payment received for product sales to a distributor. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied and will recognize the deferred revenue related to the research and distribution agreement once the milestones are satisfied or over the expected obligation period of the agreement once this amount is reasonably determinable.

Revenue Recognition

Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.

Selling, General and Administrative

Selling, general and administrative costs include personnel costs and related expenses for the Company's sales, marketing, general management and administrative staff, recruitment, costs related to the Company's commercialization efforts in Europe, professional service fees, professional license, business development and certain general legal activities.

Research and Development

Research and development costs include the costs of materials used for R&D and clinical trials, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liasons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company's proprietary drug delivery system. All such costs are charged to expense when incurred.

Stock Based Compensation

The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders' requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath's common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath's stock over the option's expected term, the risk-free interest rate over the option's expected term, and Delcath's expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

Income Taxes

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 "Income Taxes." Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company's income tax returns were prepared on the cash basis of accounting through December 31, 2008. The Company filed Form 3115, Application for Change in Method of Accounting, to change its tax accounting method from cash basis to accrual basis for years beginning after December 31, 2008. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. See Note 11 for additional information.

Net Loss per Common Share

For the years ended December 31, 2012, 2011, and 2010 potential common shares from the exercise of options and warrants and the unvested shares of restricted stock were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:

	2012		2011		2010
Stock options		4,788,887		4,129,749		3,760,650
Unvested restricted shares		501,468		193,532		67,590
Warrants		5,642,580		2,512,934		2,512,934
Total		10,932,935		6,836,215		6,341,174

Segment Information

The Company currently operates in one business segment, which is the development and commercialization of the CHEMOSAT/Melblez Kit system. A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Recently Adopted Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2011-04 which was issued to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and IFRS. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level 3 fair value measurements. The Company adopted this guidance on January 1, 2012, and its adoption did not significantly impact the Company's consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05 which provides new guidance on the presentation of comprehensive income. ASU 2011-05 eliminates the option to report other comprehensive income and its components in the statement of changes in stockholders' equity and instead requires an entity to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement or in two separate but consecutive statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. The adoption of this ASU only requires a change in the format of the current presentation. The Company adopted this guidance on January 1, 2012, and its adoption did not significantly impact the Company's consolidated financial statements.

Inventories

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

Inventories

(4)

Inventories

Inventories consist of:

	December 31, 2012		December 31, 2011
Raw materials	$	197	$	-
Work-in-process		405		-
Finished goods		503		-
Total	$	1,105	$	-

Delcath transitioned from a development stage company to a commercial organization with operational activities in April 2012. A portion of the Company's inventory was purchased prior to obtaining authorization to affix the CE Mark to its Generation Two Delcath Hepatic CHEMOSAT® Delivery System in April 2012, including components used in the kits sold during the twelve months ended December 31, 2012. As a result, some of the costs of sales related to recognized and deferred revenue was expensed in earlier periods.

Property, Plant, and Equipment

12 Months Ended

Dec. 31, 2012

Property, Plant, and Equipment [Abstract]

Property, Plant, and Equipment

(5) Property, Plant, and Equipment

Property, plant, and equipment consists of:

	December 31, 2012		December 31, 2011
Leaseholds	$	1,716	$	1,148
Furniture		952		880
Equipment		1,473		1,371
Computers		2,141		1,212
Buildings and Land		603		154
		6,885		4,765
Accumulated depreciation		(2,843)		(1,512)
Total	$	4,042	$	3,253

Depreciation expense for the years ended December 31, 2012, 2011, and 2010 was $1.3 million, $1.0 million, and $0.5 million, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2012

Accrued Expenses [Abstract]

Accrued Expenses

(6)	Accrued Expenses

Accrued expenses include the following:

(in thousands)	December 31, 2012		December 31, 2011
Compensation, excluding taxes	$	1,933	$	1,688
Professional fees		1,437		1,227
Contract Research Organization		1,283		1,800
Other1		1,137		758
Total accrued liabilities	$	5,790	$	5,473

1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2012 and 2011.

Assets and Liabilities Measured at Fair Value

12 Months Ended

Dec. 31, 2012

Assets and Liabilities Measured at Fair Value [Abstract]

Assets and Liabilities Measured at Fair Value

(7)	Assets and Liabilities Measured at Fair Value

Derivative Financial Instruments

As disclosed in Note 8, the Company allocated proceeds to the warrants issued in connection with a private placement and recent public offering that were classified as liabilities and accounted for as a derivative instrument in accordance with ASC 815. The valuation of the warrants is determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath's stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company's historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

Money Market Funds and Treasury Bills

The Company has determined that the inputs associated with the fair value determination are based on quoted prices (unadjusted) and as a result the investments are classified within Level 1 of the fair value hierarchy.

The table below presents the Company's assets and liabilities measured at fair value on a recurring basis as of December 31, 2012 and 2011, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Level 1				Level 2				Level 3				Balance at December 31,
(in thousands)	2012		2011		2012		2011		2012		2011		2012		2011
Assets
Money market funds	$	1,967	$	25,417		—		—		—		—	$	1,967	$	25,417
Liabilities
Derivative instrument liabilities		—		—		—		—	$	3,427	$	2,439	$	3,427	$	2,439

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Derivative
Balance at December 31,2009	$	11,207
Total increase in the liability included in earnings		15,951
Fair value of warrants exercised or expired		(9,153	)
Balance at December 31, 2010	$	18,005
Total change in the fair value of the liability included in earnings		(15,566	)
Balance at December 31, 2011	$	2,439
Total change in the fair value of the liability included in earnings		(2,159	)
Fair value of warrants issued		4,055
Fair value of warrants exercised or expired		(908	)
Balance at December 31, 2012	$	3,427

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

Stockholders' Equity

(8) Stockholders' Equity

Stock Issuances

In September 2007, the Company completed the sale of 3,833,108 shares of its common stock and the issuance of warrants to purchase 1,916,554 common shares (the "2007 Warrants") in a private placement to institutional and accredited investors. The Company received net proceeds of $13.3 million in this transaction. The Company allocated $4.3 million of those proceeds to the 2007 Warrants (see below). In accordance with the provisions of the 2007 Warrant agreement, both the exercise price and number of warrants were adjusted following the Company's May 31, 2012 sale of common stock and warrants and became exercisable at $1.49 per share with 3,392,592 warrants outstanding. The 2007 Warrants expired on September 21, 2012. Approximately 3.0 million warrants were exercised during the quarter ended September 30, 2012. The remaining liability after the warrant exercises was credited to pre-tax derivative instrument income.

In June 2009, the Company completed the sale of 869,565 shares of its common stock and the issuance of warrants to purchase 1,043,478 common shares (the "2009 Warrants") pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants (see below). As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company's May 31, 2012 sale of common stock and warrants. At December 31, 2012, the 2009 Warrants were exercisable at $1.20 per share with 1,043,478 warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

In August 2010, the Company completed the sale of 5,185,000 shares of its common stock pursuant to an underwriting agreement, raising approximately $33.5 million after expenses. The shares were issued pursuant to an effective registration statement on Form S-3 (333-165677).

In July 2011, the Company completed the sale of 5,000,000 shares of its common stock pursuant to an underwriting agreement, raising approximately $23.5 million after expenses. The shares were issued pursuant to an effective registration statement on Form S-3 (333-165677).

In December 2011, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC to sell shares of the Company's common stock, par value $.01 per share, having aggregate sales proceeds of $39.8 million, from time to time, through an "at the market" equity offering program under which Cowen and Company, LLC will act as sales agent. As of December 31, 2012, the Company had sold approximately 8.1 million shares of its common stock through the program for net proceeds after related expenses of approximately $17.6 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-165677). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of December 31, 2012, there was approximately $21.5 million available under this program.

In May 2012, the Company completed the sale of 15,333,340 shares of its common stock and the issuance of warrants to purchase 4,600,002 common shares (the "2012 Warrants") pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. At December 31, 2012, the 2012 Warrants were exercisable at $1.20 per share with 4,599,102 warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3 (333-178819).

In December 2012, the Company entered into a Common Stock Purchase Agreement (Purchase Agreement) with Terrapin Opportunity, L.P. (Terrapin). The Purchase Agreement provides that Terrapin is committed to purchase up to $35,000,000 of our common stock over the 24-month term of the Purchase Agreement.. As of December 31, 2012, the Company has sold approximately 1.7 million shares of its common stock through the program for net proceeds after related expenses of approximately $1.9 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of December 31, 2012, there was approximately $32.9 million available under this program.

Stock Option Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the "Plans") under which 3,000,000, and 6,500,000 shares, respectively, were reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In May 2012, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 2,300,000 shares, from 4,200,000 to 6,500,000 upon a favorable vote by the Company's stockholders. A stock option grant allows the holder of the option to purchase a share of the Company's common stock in the future at a stated price. The Plans are administered by the Compensation and Stock Option Committee of the board of directors which determines the individuals to whom awards shall be granted as well as the type, terms and conditions of each award, the option price and the duration of each award.

Options granted under the Plans vest as determined by the Company's Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2012, 2011, and 2010 is as follows:

	Number of Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at December 31, 2009		3,345,000		$	1.23–6.18	$	3.72		6.58
Granted		700,650			5.28-15.54		9.81
Expired		(120,000	)		2.78-3.59		3.25
Forfeited		(25,000	)		4.12-6.18		4.81
Exercised		(140,000	)		1.43-6.18		3.52
Outstanding at December 31, 2010		3,760,650		$	1.23-15.54	$	4.88		6.65
Granted		671,326			2.00-9.18		5.72
Expired		(120,000	)		3.28		3.28
Forfeited		(136,900	)		1.40-9.93		4.65
Exercised		(45,327	)		2.44-3.28		3.18
Outstanding at December 31, 2011		4,129,749		$	1.23-15.54	$	5.09		6.38
Granted		1,207,452			1.43-4.60		3.80
Expired		(420,000	)		1.88-5.85		4.81
Forfeited		(128,314	)		2.26-9.18		5.05
Exercised		-
Outstanding at December 31, 2012		4,788,887		$	1.23-15.54	$	4.79		6.88

Exercisable at December 31, 2012		3,105,535		$	1.23-15.54	$	$4.85		5.80

The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2012, 2011 and 2010:

	Year Ended December 31,
	2012			2011			2010
Weighted average risk-free interest rate		1.11	%		2.07	%		2.54	%
Weighted average expected volatility		79.89	%		74.64	%		73.80	%
Expected volatility		77.37-84.81	%		73.88% - 79.11	%		72.16% - 75.40	%
Dividend yield		0.00	%		0.00	%		0.00	%
Weighted average expected option term (in years)		6.17			6.00			5.87
Weighted average grant date fair value	$	2.59		$	3.79		$	6.30

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company's historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during the second of half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period.

A summary of the Company's non-vested options to purchase shares as of December 31, 2012 and changes during the twelve months ended December 31, 2012 and December 31, 2011 are presented below:

	Non-Vested Options
	Number of Options			Weighted Average Exercise Price

Non-vested at December 31, 2010		1,362,316		$	6.39
Granted		670,826			5.72
Vested		(812,874	)		5.60
Forfeited		(61,900	)		8.58
Non-vested at December 31, 2011		1,158,368		$	6.44
Granted		1,207,452			3.80
Vested		(570,518	)		6.38
Forfeited		(111,950	)		4.79
Non-vested at December 31, 2012		1,683,352		$	4.68

Compensation expense recognized relating to stock options granted to employees (in millions):

	2012			2011			2010
Selling, general and administrative		$	1.7		$	2.2		$	2.5
Research and development			1.1			1.4			1.1
Total		$	2.8		$	3.6		$	3.6

Additional compensation expense of $2.0 million, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 1.4 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2012 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company's closing stock price of $1.23 as of December 31, 2012, which would have been received by the option holders had those option holders exercised their options as of that date.

A summary of the Company's restricted stock activity as of December 31, 2012 and changes during the twelve months ended December 31, 2012 and December 31, 2011 are presented below:

	Restricted Stock Activity
	Number of Shares			Weighted Average Grant Date Fair Value

Non-vested at December 31, 2010		67,590		$	6.71
Granted		188,277			5.67
Vested		(47,270	)		5.62
Forfeited		(15,065	)		8.35
Non-vested at December 31, 2011		193,532		$	5.84
Granted		429,720			2.83
Vested		(100,751	)		6.18
Forfeited		(21,033	)		4.39
Non-vested at December 31, 2012		501,468		$	3.26

Compensation expense recognized relating to restricted stock granted to employees (in millions):

	2012			2011			2010
Selling, general and administrative		$	0.7		$	0.5		$	0.8
Research and development			0.3			0.1			0.8
Total		$	1.0		$	0.6		$	1.6

Additional compensation expense of $0.7 million relating to the unvested portion of restricted stock granted, is expected to be recognized over a remaining average period of 1.2 years.

Warrants

The Company allocated part of the proceeds of a private placement in 2007 and public offerings in 2009 and 2012 of the Company's common stock to warrants issued in connection with those transactions. The Company determined that these warrants should be classified as liabilities rather than equity as the terms of the warrants provide for potential adjustment in the exercise price and are therefore considered to be derivative instrument liabilities that are subject to mark-to-market adjustment each period. As of December 31, 2012, the 2009 and 2012 Warrants are classified as derivative instrument liabilities. The 2007 Warrants were exercised or expired in September 2012 and are no longer part of the warrant liability on the balance sheet.

The valuation of the warrants is determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820-10-35. There are six inputs: the closing price of the Company's common stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath's stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on our historical practice of not granting dividends. The closing price of the Company's common stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10-35-40). The riskless rate of return is a Level 2 input as defined in ASC 820-10-35-48, while the historical volatility is a Level 3 input as defined in ASC 820-10-55-22. Since the lowest level input is a Level 3, the Company determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the year ended December 31, 2012, the Company recorded pre-tax derivative instrument income of $2.2 million. The resulting derivative instrument liabilities totaled $3.4 million at December 31, 2012. Management expects that the warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2012 was determined by using an option pricing model assuming the following:

	2012 Warrants			2009 Warrants
Expected volatility		86.08	%		87.14	%
Risk-free interest rates		0.30	%		0.20	%
Expected life (in years)		2.4			1.4

A summary of warrant activity is as follows:

	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at December 31, 2009		3,746,184		$	3.44–3.91	$	3.52		3.08
Issued		–
Exercised		(1,159,000	)		3.44–3.91		3.52
Expired		(74,250	)		3.91		3.91
Outstanding at December 31, 2010		2,512,934		$	3.44-3.60	$	3.51		2.45
Issued		–
Exercised		–
Expired		–
Outstanding at December 31, 2011		2,512,934		$	3.44-3.60	$	3.51		1.45
Issued		6,523,120			1.49-3.03		1.65
Exercised		(2,975,457	)		1.49-1.65		1.49
Expired		(418,017	)		1.49		1.49
Outstanding at December 31, 2012		5,642,580		$	1.20	$	1.20		2.24

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Loan and Security Agreement

12 Months Ended

Dec. 31, 2012

Loan and Security Agreement [Abstract]

Loan and Security Agreement

(9)	Loan and Security Agreement

In April 2012, the Company entered into a four-year Loan and Security Agreement (the "Credit Agreement") with Silicon Valley Bank ("SVB"), as lender. The Credit Agreement consists of a revolving credit facility in an amount equal to the lesser of $20,000,000 and the Company's Borrowing Base (as defined in the Credit Agreement). In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB. At December 31, 2012, the Company had not used any of the available funds.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Commitments

12 Months Ended

Dec. 31, 2012

Commitments [Abstract]

Commitments

(10)	Commitments

Operating Leases

In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space in New York, New York with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010 and provides for total annual base rental payments of $457,337 during years 1-3 and the first half of year 4 of the Initial Lease term, and of $491,853 during the second half of year 4 and years 5-7 of the Lease term. The Initial Lease also requires the Company to pay customary building operating expenses and a pro-rata share of real estate taxes.

In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space in New York, New York. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Lease Amendment provides for annual base rent of $504,078 for years 1-5 and of $547,533 for years 6-11 of the Lease Amendment term. In addition, the Lease Amendment provides for total base rent on the space leased under the Initial Lease of $543,627 for the extended term of November 2017 – March 2021. Combined, the Initial Lease and the Lease Amendment provide for annual rent of $961,000 in 2012, $970,000 in 2013, $996,000 in 2014 and 2015, $1.0 million in 2016, and $1.1 million in 2017-2020.

In July 2012, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on July 18, 2012 and is effective for a one year period with an option to extend the lease for an additional year. The agreement provides for total annual base rent of $42,000.

In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath's European headquarters. The Lease is for a term of ten years, commencing August 2, 2011; although Delcath Limited has the option to terminate the Lease after the fifth year upon not less than six months notice. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2012 conversion rate): Year 1 – €106,051 ($140,179), Year 2 – €134,974 ($178,410), Year 3 – €159,077 ($210, 269) and Years 4 and 5 – €183,179 ($242,127). Annual lease amounts in years 6 through 10 are subject to adjustment based upon the percentage increase in the consumer price index as published by the Ireland Central Statistics Office. Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited's payment obligations and performance of the Lease are guaranteed by Delcath.

In May 2012, the Company entered into an agreement to purchase 10,320 square feet located at 566 Queensbury Avenue, Queensbury, NY (the "Facility"), which was previously leased. The purchase price for the Facility was $440,000 as stated in the initial lease agreement, which commenced on September 1, 2009.

In June 2012, the Company entered into an agreement to lease 18,000 square feet at Suites 2 and 3 Country Club Road, Queensbury, NY for a three year period. This amends the initial lease at 2 Country Club Road, which commenced on November 12, 2010. The location houses a portion of the Company's research and manufacturing operations. The lease provides for annual base rent of $216,000, as well as the payment of customary building operating expenses and real estate taxes.

Future minimum lease payments under all operating leases at December 31, 2012 are as follows (in thousands):

Year Ended December 31:	Future Lease Payment
2013	$	1,422
2014		1,460
2015		1,328
2016		1,278
2017		1,294
	$	6,782

Rent expense totaled approximately $1.5 million, $1.2 million and $0.5 million, for the years ended December 31, 2012, 2011 and 2010, respectively.

Letters of Credit

Under the terms of the lease agreement for office space in New York City, the Company is required to maintain a letter of credit in the amount of $881,297. The letter of credit expires on February 1, 2014 if not renewed by the Company.

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Income Taxes

(11) Income Taxes

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

	Year Ended December 31,
(in thousands)	2012			2011			2010
Income taxes using U.S. federal statutory rate	$	(17,621	)	$	(10,501	)	$	(15,872	)
Amoritization of Gain on IP Migration		754			–			–
State income taxes, net of federal benefit		(4,299	)		(3,418	)		(4,276	)
Foreign rate differential		3,716			52			–
Valuation allowance		17,561			20,563			15,041
Derivative charge		(734	)		(5,292	)		5,423
Stock option exercises and cancellations		310			102			–
Research and development credits		326			(1,633	)		(519	)
Other		(13	)		127			203
Total	$	–		$	–		$	–

Significant components of the Company's deferred tax assets are as follows:

(in thousands)	2012		2011
Deferred tax assets:
Employee compensation accruals	$	6,176	$	4,973
Accrued liabilities		299		283
Research tax credits		2,382		2,708
Other		31		3
Net operating losses		63,765		47,118
Total deferred tax assets		72,653		55,085

Deferred tax liability:
Total deferred tax liabilities		–		–

Valuation allowance		72,653		55,085
Net deferred tax assets	$	–	$	–

As of December 31, 2012 and December 31, 2011, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $138.1 million and $122.1 million, respectively. A portion of the federal amount, $8.6 million, is subject to an annual limitation of approximately $123,000 as a result of a change in the Company's ownership through May 2003, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitation, approximately $131.9 million is available to offset future federal taxable income which will expire between 2018 and 2032. As of December 31, 2012 and December 31, 2011, the Company had net operating loss carryforwards for state and city income tax purposes of approximately $231.0 million and $180.2 million, respectively, which expire through 2032. As of December 31, 2012 and December 31, 2011, the Company had a net operating loss carryforward for foreign income tax purposes of $6.7 million and $0.2 million, respectively, which have indefinite carryforward periods. There were no foreign net operating losses prior to 2011.

The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. Pursuant to ASC 718, the benefit will be recognized and recorded to additional paid-in capital when the benefit is realized through the reduction of taxes payable. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company's valuation allowance increased by approximately $17.6 million, $20.5 million, $15.0 million, $5.9 million, and $3.2 million in 2012, 2011, 2010, 2009, and 2008, respectively.

The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

The Company is subject to income tax in the U.S., the Republic of Ireland, and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The periods from December 31, 2004 to December 31, 2012 remain open to examination by the U.S. Internal Revenue Service, and international and state tax authorities.

Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2012

Quarterly Financial Data (Unaudited) [Abstract]

Quarterly Financial Data (Unaudited)

(12)	Quarterly Financial Data (Unaudited)

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2012 and 2011.

	2012 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(14,554	)	$	(15,316	)	$	(12,175	)	$	(11,825	)
Change in fair value of warranty liability, net		(338	)		917			446			1,134
Net loss		(14,889	)		(14,512	)		(11,813	)		(10,657	)
Basic and diluted loss per share		(0.31	)		(0.26	)		(0.18	)		(0.14	)

	2011 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(7,814	)	$	(10,486	)	$	(12,181	)	$	(15,974	)
Change in fair value of warranty liability, net		5,966			5,027			3,872			702
Net loss		(1,848	)		(5,459	)		(8,309	)		(15,268	)
Basic and diluted loss per share		(0.04	)		(0.13	)		(0.18	)		(0.32	)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Subsequent Events

12 Months Ended

Dec. 31, 2012

Subsequent Events [Abstract]

Subsequent Events

(13)	Subsequent Events

During the first quarter through February 28, 2013, the Company sold approximately 14.2 million shares of our common stock under the Sales Agreement through an "at the market" equity offering program for net proceeds of approximately $20.9 million before related expenses. The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. There are no proceeds remaining under the program.

Delcath completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies [Abstract]

Use of Estimates

Cash Equivalents and Concentrations of Credit Risk

Investments

Accounts Receivable

Inventories

Property, Plant and Equipment

Derivative Instrument Liability

Fair Value Measurements

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity.

Deferred Revenue

Revenue Recognition

Selling, General and Administrative

Research and Development

Stock Based Compensation

Income Taxes

Net Loss per Common Share

Shares excluded from the computation of diluted EPS:

	2012		2011		2010
Stock options		4,788,887		4,129,749		3,760,650
Unvested restricted shares		501,468		193,532		67,590
Warrants		5,642,580		2,512,934		2,512,934
Total		10,932,935		6,836,215		6,341,174

Segment Information

Recently Adopted Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies [Abstract]

Shares excluded from the computation of diluted EPS

Shares excluded from the computation of diluted EPS:

	2012		2011		2010
Stock options		4,788,887		4,129,749		3,760,650
Unvested restricted shares		501,468		193,532		67,590
Warrants		5,642,580		2,512,934		2,512,934
Total		10,932,935		6,836,215		6,341,174

Inventories (Tables)

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

Schedule of inventories

Inventories consist of:

	December 31, 2012		December 31, 2011
Raw materials	$	197	$	-
Work-in-process		405		-
Finished goods		503		-
Total	$	1,105	$	-

Property, Plant, and Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Property, Plant, and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consists of:

	December 31, 2012		December 31, 2011
Leaseholds	$	1,716	$	1,148
Furniture		952		880
Equipment		1,473		1,371
Computers		2,141		1,212
Buildings and Land		603		154
		6,885		4,765
Accumulated depreciation		(2,843)		(1,512)
Total	$	4,042	$	3,253

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2012

Accrued Expenses [Abstract]

Schedule of accrued expenses

Accrued expenses include the following:

(in thousands)	December 31, 2012		December 31, 2011
Compensation, excluding taxes	$	1,933	$	1,688
Professional fees		1,437		1,227
Contract Research Organization		1,283		1,800
Other1		1,137		758
Total accrued liabilities	$	5,790	$	5,473

1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2012 and 2011.

Assets and Liabilities Measured at Fair Value (Tables)

12 Months Ended

Dec. 31, 2012

Assets and Liabilities Measured at Fair Value [Abstract]

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Level 1				Level 2				Level 3				Balance at December 31,
(in thousands)	2012		2011		2012		2011		2012		2011		2012		2011
Assets
Money market funds	$	1,967	$	25,417		—		—		—		—	$	1,967	$	25,417
Liabilities
Derivative instrument liabilities		—		—		—		—	$	3,427	$	2,439	$	3,427	$	2,439

Fair Value Measurements Using Significant Unobservable Inputs

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Derivative
Balance at December 31,2009	$	11,207
Total increase in the liability included in earnings		15,951
Fair value of warrants exercised or expired		(9,153	)
Balance at December 31, 2010	$	18,005
Total change in the fair value of the liability included in earnings		(15,566	)
Balance at December 31, 2011	$	2,439
Total change in the fair value of the liability included in earnings		(2,159	)
Fair value of warrants issued		4,055
Fair value of warrants exercised or expired		(908	)
Balance at December 31, 2012	$	3,427

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2012

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option activity

	Number of Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at December 31, 2009		3,345,000		$	1.23–6.18	$	3.72		6.58
Granted		700,650			5.28-15.54		9.81
Expired		(120,000	)		2.78-3.59		3.25
Forfeited		(25,000	)		4.12-6.18		4.81
Exercised		(140,000	)		1.43-6.18		3.52
Outstanding at December 31, 2010		3,760,650		$	1.23-15.54	$	4.88		6.65
Granted		671,326			2.00-9.18		5.72
Expired		(120,000	)		3.28		3.28
Forfeited		(136,900	)		1.40-9.93		4.65
Exercised		(45,327	)		2.44-3.28		3.18
Outstanding at December 31, 2011		4,129,749		$	1.23-15.54	$	5.09		6.38
Granted		1,207,452			1.43-4.60		3.80
Expired		(420,000	)		1.88-5.85		4.81
Forfeited		(128,314	)		2.26-9.18		5.05
Exercised		-
Outstanding at December 31, 2012		4,788,887		$	1.23-15.54	$	4.79		6.88

Exercisable at December 31, 2012		3,105,535		$	1.23-15.54	$	$4.85		5.80

Assumptions used to determine the fair value of stock options

	Year Ended December 31,
	2012			2011			2010
Weighted average risk-free interest rate		1.11	%		2.07	%		2.54	%
Weighted average expected volatility		79.89	%		74.64	%		73.80	%
Expected volatility		77.37-84.81	%		73.88% - 79.11	%		72.16% - 75.40	%
Dividend yield		0.00	%		0.00	%		0.00	%
Weighted average expected option term (in years)		6.17			6.00			5.87
Weighted average grant date fair value	$	2.59		$	3.79		$	6.30

Non-vested options

A summary of the Company's non-vested options to purchase shares as of December 31, 2012 and changes during the twelve months ended December 31, 2012 and December 31, 2011 are presented below:

	Non-Vested Options
	Number of Options			Weighted Average Exercise Price

Non-vested at December 31, 2010		1,362,316		$	6.39
Granted		670,826			5.72
Vested		(812,874	)		5.60
Forfeited		(61,900	)		8.58
Non-vested at December 31, 2011		1,158,368		$	6.44
Granted		1,207,452			3.80
Vested		(570,518	)		6.38
Forfeited		(111,950	)		4.79
Non-vested at December 31, 2012		1,683,352		$	4.68

Restricted stock activity

A summary of the Company's restricted stock activity as of December 31, 2012 and changes during the twelve months ended December 31, 2012 and December 31, 2011 are presented below:

	Restricted Stock Activity
	Number of Shares			Weighted Average Grant Date Fair Value

Non-vested at December 31, 2010		67,590		$	6.71
Granted		188,277			5.67
Vested		(47,270	)		5.62
Forfeited		(15,065	)		8.35
Non-vested at December 31, 2011		193,532		$	5.84
Granted		429,720			2.83
Vested		(100,751	)		6.18
Forfeited		(21,033	)		4.39
Non-vested at December 31, 2012		501,468		$	3.26

Warrant activity

A summary of warrant activity is as follows:

	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at December 31, 2009		3,746,184		$	3.44–3.91	$	3.52		3.08
Issued		–
Exercised		(1,159,000	)		3.44–3.91		3.52
Expired		(74,250	)		3.91		3.91
Outstanding at December 31, 2010		2,512,934		$	3.44-3.60	$	3.51		2.45
Issued		–
Exercised		–
Expired		–
Outstanding at December 31, 2011		2,512,934		$	3.44-3.60	$	3.51		1.45
Issued		6,523,120			1.49-3.03		1.65
Exercised		(2,975,457	)		1.49-1.65		1.49
Expired		(418,017	)		1.49		1.49
Outstanding at December 31, 2012		5,642,580		$	1.20	$	1.20		2.24

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation expense recognized granted to employees

Compensation expense recognized relating to stock options granted to employees (in millions):

	2012			2011			2010
Selling, general and administrative		$	1.7		$	2.2		$	2.5
Research and development			1.1			1.4			1.1
Total		$	2.8		$	3.6		$	3.6

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation expense recognized granted to employees

Compensation expense recognized relating to restricted stock granted to employees (in millions):

	2012			2011			2010
Selling, general and administrative		$	0.7		$	0.5		$	0.8
Research and development			0.3			0.1			0.8
Total		$	1.0		$	0.6		$	1.6

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Assumptions used to determine the fair value of stock options

	2012 Warrants			2009 Warrants
Expected volatility		86.08	%		87.14	%
Risk-free interest rates		0.30	%		0.20	%
Expected life (in years)		2.4			1.4

Commitments (Tables)

12 Months Ended

Dec. 31, 2012

Commitments [Abstract]

Future minimum lease payments under all operating leases

Future minimum lease payments under all operating leases at December 31, 2012 are as follows (in thousands):

Year Ended December 31:	Future Lease Payment
2013	$	1,422
2014		1,460
2015		1,328
2016		1,278
2017		1,294
	$	6,782

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Income tax reconciliation

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

	Year Ended December 31,
(in thousands)	2012			2011			2010
Income taxes using U.S. federal statutory rate	$	(17,621	)	$	(10,501	)	$	(15,872	)
Amoritization of Gain on IP Migration		754			–			–
State income taxes, net of federal benefit		(4,299	)		(3,418	)		(4,276	)
Foreign rate differential		3,716			52			–
Valuation allowance		17,561			20,563			15,041
Derivative charge		(734	)		(5,292	)		5,423
Stock option exercises and cancellations		310			102			–
Research and development credits		326			(1,633	)		(519	)
Other		(13	)		127			203
Total	$	–		$	–		$	–

Significant components of deferred tax assets

Significant components of the Company's deferred tax assets are as follows:

(in thousands)	2012		2011
Deferred tax assets:
Employee compensation accruals	$	6,176	$	4,973
Accrued liabilities		299		283
Research tax credits		2,382		2,708
Other		31		3
Net operating losses		63,765		47,118
Total deferred tax assets		72,653		55,085

Deferred tax liability:
Total deferred tax liabilities		–		–

Valuation allowance		72,653		55,085
Net deferred tax assets	$	–	$	–

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2012

Quarterly Financial Data (Unaudited) [Abstract]

Selected quarterly financial data

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2012 and 2011.

	2012 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(14,554	)	$	(15,316	)	$	(12,175	)	$	(11,825	)
Change in fair value of warranty liability, net		(338	)		917			446			1,134
Net loss		(14,889	)		(14,512	)		(11,813	)		(10,657	)
Basic and diluted loss per share		(0.31	)		(0.26	)		(0.18	)		(0.14	)

	2011 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(7,814	)	$	(10,486	)	$	(12,181	)	$	(15,974	)
Change in fair value of warranty liability, net		5,966			5,027			3,872			702
Net loss		(1,848	)		(5,459	)		(8,309	)		(15,268	)
Basic and diluted loss per share		(0.04	)		(0.13	)		(0.18	)		(0.32	)

Description of Business (Details)	12 Months Ended
Description of Business (Details)	Dec. 31, 2012
Description of Business and Summary of Significant Accounting Policies [Abstract]
Number of catheter insertions involved in Delcath chemosaturation system	3

Summary of Significant Accounting Policies (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) shares	Dec. 31, 2011 shares	Dec. 31, 2010 shares
Cash Equivalents and Concentrations of Credit Risk [Abstract]
Maximum number of months of investments with original maturities from date of acquisition to be cash equivalents	3 months
Accounts Receivable [Abstract]
Uncollectable, accounts receivable \| $	$ 0
Inventories [Abstract]
Reserves for expired, obsolete, or slow-moving inventory \| $	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted EPS (in shares)	10,932,935	6,836,215	6,341,174
Segment Information [Abstract]
Number of business segments	1
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted EPS (in shares)	4,788,887	4,129,749	3,760,650
Unvested restricted shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted EPS (in shares)	501,468	193,532	67,590
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted EPS (in shares)	5,642,580	2,512,934	2,512,934

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Inventories [Abstract]
Raw materials	$ 197	$ 0
Work-in-process	405	0
Finished goods	503	0
Total	$ 1,105	$ 0

Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 6,885	$ 4,765
Accumulated depreciation	(2,843)	(1,512)
Total	4,042	3,253
Depreciation expense	1,331	1,035	$ 472
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,716	1,148
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	952	880
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,473	1,371
Computers [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,141	1,212
Buildings and Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 603	$ 154

Accrued Expenses (Details) - USD ($)
$ in Thousands

Dec. 31, 2012

Dec. 31, 2011

Accrued Expenses [Abstract]

Compensation, excluding taxes

$ 1,933

$ 1,688

Professional fees

1,437

1,227

Contract Research Organization

1,283

1,800

Other

^[1]

1,137

758

Total accrued liabilities

$ 5,790

$ 5,473

Maximum percentage of current liabilities accrued (in hundredths)

5.00%

[1]	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2012 and 2011.

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Assets and Liabilities Measured at Fair Value [Abstract]
Number of inputs used for valuation of warrants	6
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 2,439	$ 18,005	$ 11,207
Total change in the fair value of the liability included in earnings	(2,159)	(15,566)	15,951
Fair value of warrants issued	4,055
Fair value of warrants exercised or expired	(908)		(9,153)
Ending balance	3,427	2,439	$ 18,005
Recurring [Member] \| Derivative instruments liabilities [Member]
Liabilities [Abstract]
Total Liabilities	3,427	2,439
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 1 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 2 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	3,427	2,439
Recurring [Member] \| Money market funds [Member]
Assets [Abstract]
Total Assets	1,967	25,417
Recurring [Member] \| Money market funds [Member] \| Level 1 [Member]
Assets [Abstract]
Total Assets	1,967	25,417
Recurring [Member] \| Money market funds [Member] \| Level 2 [Member]
Assets [Abstract]
Total Assets	0	0
Recurring [Member] \| Money market funds [Member] \| Level 3 [Member]
Assets [Abstract]
Total Assets	$ 0	$ 0

Stockholders' Equity (Details)	1 Months Ended	3 Months Ended								12 Months Ended
Stockholders' Equity (Details)	May 31, 2012 shares	Dec. 31, 2012 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) $ / shares shares	Dec. 31, 2009 USD ($) $ / shares shares	Dec. 31, 2007 USD ($) shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 $ / shares shares	Dec. 31, 2009 USD ($) $ / shares shares
Stock Issuances [Abstract]
Sale of stock, net of expenses (in shares) \| shares										15,333,340	5,000,000	5,185,000	869,565	3,833,108
Proceeds from issuance of private placement \| $													$ 3,000,000	$ 13,300,000
Net proceeds from issuance of private placement \| $										$ 21,100,000			$ 2,700,000
Net proceeds from issuance of common stock \| $											$ 23,500,000	$ 33,500,000
Derivative instrument income \| $		$ 1,134,000	$ 446,000	$ 917,000	$ (338,000)	$ 702,000	$ 3,872,000	$ 5,027,000	$ 5,966,000	$ 2,200,000
Derivative instrument liabilities \| $															$ 3,400,000
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares) \| shares					4,129,749				3,760,650	4,129,749	3,760,650	3,345,000
Granted (in shares) \| shares										1,207,452	671,326	700,650
Expired (in shares) \| shares										(420,000)	(120,000)	(120,000)
Forfeited (in shares) \| shares										(128,314)	(136,900)	(25,000)
Exercised (in shares) \| shares										0	(45,327)	(140,000)
Outstanding, end of period (in shares) \| shares		4,788,887				4,129,749				4,788,887	4,129,749	3,760,650	3,345,000
Exercisable (in shares) \| shares															3,105,535
Stock Options, Exercise Price per Share [Roll Forward]
Expired (in dollars per share)											$ 3.28
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)					$ 5.09				$ 4.88	$ 5.09	4.88	$ 3.72
Granted (in dollars per share)										3.80	5.72	9.81
Expired (in dollars per share)										4.81	3.28	3.25
Forfeited (in dollars per share)										5.05	4.65	4.81
Exercised (in dollars per share)											3.18	3.52
Outstanding, end of period (in dollars per share)		$ 4.79				$ 5.09				$ 4.79	$ 5.09	$ 4.88	$ 3.72
Exercisable (in dollars per share)															$ 4.85
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding										6 years 10 months 17 days	6 years 4 months 17 days	6 years 7 months 24 days	6 years 6 months 29 days
Exercisable										5 years 9 months 18 days
Cowen and Company, LLC [Member]
Stock Issuances [Abstract]
Sale of stock, net of expenses (in shares) \| shares										8,100,000
Proceeds from issuance of private placement \| $										$ 21,500,000
Net proceeds from issuance of common stock \| $										$ 17,600,000	$ 39,800,000
Shares available under program (in shares) \| shares															21,500,000
Common stock, par value under sales agreement (in dollars per share)																$ 0.01
Terrapin Opportunity, L.P. [Member]
Stock Issuances [Abstract]
Sale of stock, net of expenses (in shares) \| shares										1,700,000
Proceeds from issuance of private placement \| $										$ 1,900,000
Shares available under program (in shares) \| shares															32,900,000
Amount to be purchased by party under agreement \| $										$ 35,000,000
Term of purchase agreement										24 months
Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)					1.23				1.23	$ 1.23	$ 1.23	$ 1.23
Granted (in dollars per share)										1.43	2.00	5.28
Expired (in dollars per share)										1.88		2.78
Forfeited (in dollars per share)										2.26	1.40	4.12
Exercised (in dollars per share)											2.44	1.43
Outstanding, end of period (in dollars per share)		1.23				1.23				1.23	1.23	1.23	$ 1.23
Exercisable (in dollars per share)															$ 1.23
Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)					$ 15.54				$ 15.54	15.54	15.54	6.18
Granted (in dollars per share)										4.60	9.18	15.54
Expired (in dollars per share)										5.85		3.59
Forfeited (in dollars per share)										9.18	9.93	6.18
Exercised (in dollars per share)											3.28	6.18
Outstanding, end of period (in dollars per share)		$ 15.54				$ 15.54				$ 15.54	$ 15.54	$ 15.54	$ 6.18
Exercisable (in dollars per share)															$ 15.54
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options										10 years
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rate (in hundredths)										1.11%	2.07%	2.54%
Weighted average expected volatility (in hundredths)										79.89%	74.64%	73.80%
Dividend yield (in hundredths)										0.00%	0.00%	0.00%
Weighted average expected option term										6 years 2 months 1 day	6 years	5 years 10 months 13 days
Weighted average grant date fair value (in dollars per share)										$ 2.59	$ 3.79	$ 6.30
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares) \| shares					1,158,368				1,362,316	1,158,368	1,362,316
Granted (in shares) \| shares										1,207,452	670,826
Vested (in shares) \| shares										(570,518)	(812,874)
Forfeited (in shares) \| shares										(111,950)	(61,900)
Non-vested, end of period (in shares) \| shares		1,683,352				1,158,368				1,683,352	1,158,368	1,362,316
Non-vested Options, Weighted Average Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)					$ 6.44				$ 6.39	$ 6.44	$ 6.39
Granted (in dollars per share)										3.80	5.72
Vested (in dollars per share)										6.38	5.60
Forfeited (in dollars per share)										4.79	8.58
Non-vested, end of period (in dollars per share)		$ 4.68				$ 6.44				$ 4.68	$ 6.44	$ 6.39
Additional compensation expense relating to stock options \| $															$ 2,000,000
Remaining average recognition period for unrecognized compensation expense										1 year 4 months 24 days
Aggregate intrinsic value of options outstanding and exercisable \| $															$ 0
Closing stock price (in dollars per share)															$ 1.23
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										$ 2,800,000	$ 3,600,000	$ 3,600,000
Stock Options [Member] \| Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										1,700,000	2,200,000	2,500,000
Stock Options [Member] \| Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										$ 1,100,000	$ 1,400,000	$ 1,100,000
Stock Options [Member] \| Minimum [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)										77.37%	7388.00%	7216.00%
Stock Options [Member] \| Maximum [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)										84.81%	7911.00%	7540.00%
Restricted Stock [Member]
Non-vested Options, Weighted Average Fair Value [Roll Forward]
Additional compensation expense relating to restricted stock \| $															$ 700,000
Remaining average recognition period for unrecognized compensation expense										1 year 2 months 12 days
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares) \| shares					193,532				67,590	193,532	67,590
Granted (in shares) \| shares										429,720	188,277
Vested (in shares) \| shares										(100,751)	(47,270)
Forfeited (in shares) \| shares										(21,033)	(15,065)
Outstanding, end of period (in shares) \| shares		501,468				193,532				501,468	193,532	67,590
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)					$ 5.84				$ 6.71	$ 5.84	$ 6.71
Granted (in dollars per share)										2.83	5.67
Vested (in dollars per share)										6.18	5.62
Forfeited (in dollars per share)										4.39	8.35
Non-vested, end of period (in dollars per share)		$ 3.26				$ 5.84				$ 3.26	$ 5.84	$ 6.71
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										$ 1,000,000	$ 600,000	$ 1,600,000
Restricted Stock [Member] \| Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										700,000	500,000	800,000
Restricted Stock [Member] \| Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation expense recognized granted to employees \| $										$ 300,000	$ 100,000	$ 800,000
2004 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for the issuance (in shares) \| shares															3,000,000
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for the issuance (in shares) \| shares															6,500,000	4,200,000
Increased number of shares (in shares) \| shares	2,300,000
2007 Warrants [Member]
Stock Issuances [Abstract]
Warrants issued (in shares) \| shares														1,916,554
Estimated fair value allocated to warrants issued \| $														$ 4,300,000
Warrants exercisable per share price (in dollars per share)		1.49								1.49					1.49
Number of warrants outstanding (in shares) \| shares		3,392,592								3,392,592					3,392,592
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) \| shares
Outstanding, end of period (in shares) \| shares		3,392,592								3,392,592
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)		1.49								1.49
2012 Warrants [Member]
Stock Issuances [Abstract]
Warrants issued (in shares) \| shares										4,600,002
Estimated fair value allocated to warrants issued \| $															$ 3,400,000
Warrants exercisable per share price (in dollars per share)		1.20								1.20					1.20
Number of warrants outstanding (in shares) \| shares		4,599,102								4,599,102					4,599,102
Term period for warrants										3 years
Fair value assumptions used to determine the value of warrants [Abstract]
Expected volatility (in hundredths)										86.08%
Risk free interest rate (in hundredths)										0.30%
Expected life (in years)										2 years 4 months 24 days
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) \| shares
Outstanding, end of period (in shares) \| shares		4,599,102								4,599,102
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)		1.20								1.20
2009 Warrants [Member]
Stock Issuances [Abstract]
Warrants issued (in shares) \| shares													1,043,478
Estimated fair value allocated to warrants issued \| $																	$ 2,200,000
Warrants exercisable per share price (in dollars per share)		1.20								1.20					1.20
Number of warrants outstanding (in shares) \| shares		1,043,478								1,043,478					1,043,478
Term period for warrants										5 years
Fair value assumptions used to determine the value of warrants [Abstract]
Expected volatility (in hundredths)										87.14%
Risk free interest rate (in hundredths)										0.20%
Expected life (in years)										1 year 4 months 24 days
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) \| shares
Outstanding, end of period (in shares) \| shares		1,043,478								1,043,478
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)		1.20								1.20
Warrants [Member]
Stock Issuances [Abstract]
Warrants exercisable per share price (in dollars per share)		1.20								1.20					1.20
Number of warrants outstanding (in shares) \| shares		5,642,580			2,512,934	2,512,934			2,512,934	2,512,934	2,512,934	3,746,184	3,746,184		5,642,580	2,512,934	3,746,184
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) \| shares					2,512,934				2,512,934	2,512,934	2,512,934	3,746,184
Issued (in shares) \| shares										6,523,120	0	0
Exercised (in shares) \| shares										(2,975,457)	0	(1,159,000)
Expired (in shares) \| shares										(418,017)	0	(74,250)
Outstanding, end of period (in shares) \| shares		5,642,580				2,512,934				5,642,580	2,512,934	2,512,934	3,746,184
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)
Expired (in dollars per share)										$ 1.49		$ 3.91
Outstanding, end of period (in dollars per share)		1.20								1.20
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)					$ 3.51				$ 3.51	$ 3.51	$ 3.51	3.52
Issued (in dollars per share)										1.65
Exercised (in dollars per share)										1.49		3.52
Expired (in dollars per share)										1.49		3.91
Outstanding, end of period (in dollars per share)		$ 1.20				$ 3.51				$ 1.20	$ 3.51	$ 3.51	$ 3.52
Weighted average remaining life										2 years 2 months 27 days	1 year 5 months 12 days	2 years 5 months 12 days	3 years 29 days
Warrants [Member] \| Minimum [Member]
Stock Issuances [Abstract]
Warrants exercisable per share price (in dollars per share)					3.44	3.44			3.44	3.44	3.44	3.44	3.44			3.44	3.44
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)					3.44				3.44	3.44	3.44	3.44
Issued (in dollars per share)										$ 1.49
Exercised (in dollars per share)										$ 1.49		$ 3.44
Outstanding, end of period (in dollars per share)						3.44					3.44	3.44	3.44
Warrants [Member] \| Maximum [Member]
Stock Issuances [Abstract]
Warrants exercisable per share price (in dollars per share)					3.60	3.60			3.60	3.60	3.60	3.91	3.91			3.60	3.91
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)					3.60				3.60	3.60	3.60	3.91
Issued (in dollars per share)										$ 3.03
Exercised (in dollars per share)										$ 1.65		$ 3.91
Outstanding, end of period (in dollars per share)						3.60					3.60	3.60	3.91

Loan and Security Agreement (Details) - Silicon Valley Bank [Member]	12 Months Ended
	Dec. 31, 2012 USD ($)
Line of Credit Facility [Line Items]
Loan and security agreement	4 years
Credit agreement, revolving credit facility	$ 20,000,000
Line of credit facility, covenant terms	In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB.
Cash and cash equivalents	$ 15,000,000

Commitments (Details)	12 Months Ended
Commitments (Details)	Dec. 31, 2012 USD ($) ft²	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2012 EUR (€) ft²
Operating Leased Assets [Line Items]
Annual base rent in year 1	$ 1,422,000
Annual base rent in year 2	1,460,000
Annual base rent in year 3	1,328,000
Annual base rent in year 4	1,278,000
Annual base rent in year 5	1,294,000
Future minimum lease payments under all operating leases [Abstract]
2013	1,422,000
2014	1,460,000
2015	1,328,000
2016	1,278,000
2017	1,294,000
Total future minimum payments due	6,782,000
Rent expense	1,500,000	$ 1,200,000	$ 500,000
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement	$ 881,297
Expiration date of letter of credit	2014-02-01
Office Space in New York, New York, Initial Lease [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	8,629			8,629
Expansion option, additional square footage of office space (in square feet) \| ft²	8,629			8,629
Annual base rent payment in years 1-3 and first half of year 4	$ 457,337
Annual base rent payment in second half of year 4 and years 5-7	491,853
Future minimum lease payments under all operating leases [Abstract]
2017-2021	$ 543,627
Office Space in New York, New York, Lease Amendment [Member]
Operating Leased Assets [Line Items]
Additional square footage of office space leased under exercise of option right (in square feet) \| ft²	8,629			8,629
Lease expiration date	Mar. 31, 2021
Annual base rent payment in years 1-5	$ 504,078
Annual base rent payment in years 6-11	547,533
Office Space in New York, New York, Initial Lease and Lease Amendment [Member]
Operating Leased Assets [Line Items]
Annual base rent in year 1	970,000
Annual base rent in year 2	996,000
Annual base rent in year 3	996,000
Annual base rent in year 4	1,000,000
Future minimum lease payments under all operating leases [Abstract]
2012	961,000
2013	970,000
2014	996,000
2015	996,000
2016	1,000,000
2017-2021	$ 1,100,000
Facility lease agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	10,320			10,320
Future minimum lease payments under all operating leases [Abstract]
Purchase price if acquired by September 1, 2009	$ 440,000
Country Club Road lease agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	18,000			18,000
Future minimum lease payments under all operating leases [Abstract]
Operating lease term	3 years
Annual base rent	$ 216,000
Park Road lease agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	6,000			6,000
Future minimum lease payments under all operating leases [Abstract]
Operating lease term	1 year
Annual base rent	$ 42,000
Delcath's European headquarters lease agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	19,200			19,200
Annual base rent in year 1	$ 140,179			€ 106,051
Annual base rent in year 2	178,410			134,974
Annual base rent in year 3	210,269			159,077
Annual base rent in year 4	242,127			183,179
Annual base rent in year 5	242,127			183,179
Future minimum lease payments under all operating leases [Abstract]
2013	140,179			106,051
2014	178,410			134,974
2015	210,269			159,077
2016	242,127			183,179
2017	$ 242,127			€ 183,179
Operating lease term	10 years
Delivery time frame of written notice, minimum	6 months

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Provision for income taxes [Abstract]
Income taxes using U.S. federal statutory rate	$ (17,621,000)	$ (10,501,000)	$ (15,872,000)
Amortization of Gain on IP Migration	754,000	0	0
State income taxes, net of federal benefit	(4,299,000)	(3,418,000)	(4,276,000)
Foreign rate differential	3,716,000	52,000	0
Valuation allowance	17,561,000	20,563,000	15,041,000	$ 5,900,000	$ 3,200,000
Derivative charge	(734,000)	(5,292,000)	5,423,000
Stock option exercises and cancellations	310,000	102,000	0
Research and development credits	326,000	(1,633,000)	(519,000)
Other	(13,000)	127,000	203,000
Total	0	0	0
Deferred tax assets [Abstract]
Employee compensation accruals	6,176,000	4,973,000
Accrued liabilities	299,000	283,000
Research tax credits	2,382,000	2,708,000
Other	31,000	3,000
Net operating losses	63,765,000	47,118,000
Total deferred tax assets	72,653,000	55,085,000
Deferred tax liability [Abstract]
Total deferred tax liabilities	0	0
Valuation allowance	72,653,000	55,085,000
Net deferred tax assets	$ 0	0
Operating Loss Carryforwards [Line Items]
Percentage of valuation allowance (in hundredths)	100.00%
Valuation allowance increased	$ 17,561,000	20,563,000	15,041,000	$ 5,900,000	$ 3,200,000
Tax benefit related to the exercise of non qualified stock options	1,000,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 138,100,000	122,100,000
Operating loss carryforwards, expiration dates	2032
Operating loss carryforwards, amount subject to limitations	$ 8,600,000
Operating loss carryforwards, annual limitation	123,000
Operating loss carryforwards, net of limitations	131,900,000
State and city [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 231,000,000	180,200,000
Operating loss carryforwards, expiration dates	2032
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 6,700,000	$ 200,000	$ 0

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Quarterly Financial Data (Unaudited) [Abstract]
Operating loss	$ (11,825)	$ (12,175)	$ (15,316)	$ (14,554)	$ (15,974)	$ (12,181)	$ (10,486)	$ (7,814)	$ 53,871	$ 46,456	$ 30,743
Change in fair value of warranty liability, net	1,134	446	917	(338)	702	3,872	5,027	5,966	2,200
Net loss	$ (10,657)	$ (11,813)	$ (14,512)	$ (14,889)	$ (15,268)	$ (8,309)	$ (5,459)	$ (1,848)	$ (51,868)	$ (30,885)	$ (46,684)
Basic and diluted loss per share (in dollars per share)	$ (0.14)	$ (0.18)	$ (0.26)	$ (0.31)	$ (0.32)	$ (0.18)	$ (0.13)	$ (0.04)	$ (0.85)	$ (0.68)	$ (1.2)

- Definition

The amount of net gains and losses recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Subsequent Events (Details) - USD ($) $ in Millions	2 Months Ended	12 Months Ended
Subsequent Events (Details) - USD ($) $ in Millions	Feb. 28, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2007
Subsequent Event [Line Items]
Common stock sold through the program (in shares)		15,333,340	5,000,000	5,185,000	869,565	3,833,108
Proceeds from issuance of common stock			$ 23.5	$ 33.5
Subsequent Event [Member] \| Sales Agreement [Member]
Subsequent Event [Line Items]
Common stock sold through the program (in shares)	14,200,000
Proceeds from issuance of common stock	$ 20.9